Form 8-K

8-K — bioAffinity Technologies, Inc.

Accession: 0001493152-26-039375

Filed: 2026-08-20

Period: 2026-08-20

CIK: 0001712762

SIC: 8731 (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH)

Item: Material Modifications to Rights of Security Holders

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0001712762

2026-08-20

0001712762

BIAF:CommonStockParValue0.007PerShareMember

2026-08-20

0001712762

BIAF:WarrantsToPurchaseCommonStockMember

2026-08-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 20, 2026

bioAffinity

Technologies, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-41463

46-5211056

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

3300

Nacogdoches Road, Suite 216

San

Antonio, Texas 78217

(Address

of principal executive offices, including zip code)

(210)

698-5334

(Registrant’s

telephone number, including area code)

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title

of each class

Trading

Symbols

Name

of each exchange on which registered

Common

Stock, par value $0.007 per share

BIAF

The

Nasdaq Stock Market LLC

(Nasdaq

Capital Market)

Warrants

to purchase Common Stock

BIAFW

The

Nasdaq Stock Market LLC

(Nasdaq

Capital Market)

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

3.03 Material Modification to Rights of Security Holders.

the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated

herein by reference.

Item

5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

previously reported in a Current Report on Form 8-K with the Securities and Exchange Commission

(the “SEC”), on April 30, 2026, bioAffinity Technologies, Inc. (the “Company”) held its annual meeting

of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders approved a proposal to amend the Company’s

certificate of incorporation to effect a reverse split of the Company’s outstanding shares of common stock, par value $0.007 (the

“Common Stock”) at a ratio of one-for-two (1-for-2) to one-for-two hundred fifty (1-for-250), with the ratio within such

range to be determined at the discretion of the Company’s board of directors (the “Board”).

Following

the Annual Meeting, the Board approved a one-for-fifteen (1-for-15) reverse split of the Company’s issued and outstanding shares

of Common Stock (the “Reverse Stock Split”). On August 20, 2026, the Company filed with the Secretary of State of the State

of Delaware a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”) to effect the

Reverse Stock Split. The Reverse Stock Split will become effective as of 4:01 p.m. Eastern Time on August 21, 2026, and the Company’s

common stock will begin trading on a split-adjusted basis when the Nasdaq Stock Market opens on August 24, 2026. The Reverse Stock Split

is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price

requirement.

When

the Reverse Stock Split becomes effective, every fifteen (15) shares of the Company’s issued and outstanding Common Stock will

be automatically combined, converted and changed into one (1) share of the Company’s Common Stock, without any change in the number

of authorized shares or the par value per share. In addition, a proportionate adjustment will be made to the per share exercise price

and the number of shares issuable upon the exercise of all outstanding stock options, restricted stock units and warrants to purchase

shares of common stock and the number of shares reserved for issuance pursuant to the Company’s equity incentive compensation plans.

The Reverse Stock Split will affect all of our stockholders uniformly and will not affect any stockholder’s

percentage ownership interests in our company, except those stockholders who would have otherwise received fractional shares who will

receive cash in lieu of such fractional shares. Holders of the Company’s Common Stock held in book-entry form or through

a bank, broker or other nominee do not need to take any action in connection with the Reverse Stock Split. Stockholders of record will

be receiving information from the Company’s transfer agent regarding their Common Stock ownership post-Reverse Stock Split.

The

Company’s Common Stock will continue to trade on the Nasdaq Stock Market LLC under the existing symbol “BIAF,” but

the security has been assigned a new CUSIP number (09076W406).

The

foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to

the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference

herein.

Item

7.01 Regulation FD Disclosure

August 20, 2026, the Company issued a press release announcing the Reverse Stock Split. A copy

of the press release is furnished to this Current Report on Form 8-K as Exhibit 99.1.

The

information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed”

for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject

to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be

incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after

the date of this Current Report, regardless of any general incorporation language in any such filing.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits.

Exhibit

No.

Exhibit

3.1

Certificate of Amendment to Certificate of Incorporation of bioAffinity Technologies, Inc.

99.1

Press release dated August 20, 2026

104

Cover

Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K

to be signed on its behalf by the undersigned hereunto duly authorized.

Date:

August 20, 2026

BIOAFFINITY

TECHNOLOGIES, INC.

By:

/s/

Maria Zannes

Name:

Maria

Zannes

Title:

President

and Chief Executive Officer

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit 3.1

FORM OF CERTIFICATE OF AMENDMENT OF

CERTIFICATE OF INCORPORATION OF

BIOAFFINITY TECHNOLOGIES, INC.

bioAffinity Technologies, Inc.

(the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby

certifies as follows:

1. This Certificate of Amendment

(the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificate of Incorporation filed with

the Secretary of State on March 26, 2014, as previously amended by that Certificate of Amendment filed with the Secretary of State on

May 31, 2016, that Certificate of Designation filed with the Secretary of State on July 13, 2017, that Certificate of Amendment filed

with the Secretary of State on November 29, 2021, that Certificate of Amendment filed with the Secretary of State on June 23, 2022, that

Certificate of Amendment filed with the Secretary of State on June 6, 2023, that Certificate of Amendment filed with the Secretary of

State on June 5, 2024, that Certificate of Amendment filed with the Secretary of State on August 13, 2025, that Certificate of Designation

filed with the Secretary of State on August 13, 2025, and that Certificate of Amendment filed with the Secretary of State on September

17, 2025 (as previously amended, the “Certificate of Incorporation”).

2. The Corporation’s Board

adopted resolutions setting forth this amendment to the Corporation’s Certificate of Incorporation declaring said amendment to be

advisable and soliciting the approval of the Corporation’s stockholders. Thereafter, the necessary number of shares as required

by statute approved this amendment at a properly noticed and duly convened meeting of the Corporation’s stockholders.

3. Section 4 of the Certificate

of Incorporation is hereby amended by adding the following paragraphs immediately after the first paragraph of Section 4:

As of August 21, 2026 at 4:01 p.m. Eastern

Time (the “Effective Time”), the shares of the Corporation’s common stock, par value $0.007 per share (the “Common

Stock”) issued and outstanding immediately prior to the Effective Time and the shares of Common Stock issued and held in the

treasury of the Corporation immediately prior to the Effective Time shall be reclassified as and combined into a smaller number of shares

such that every fifteen (15) shares of issued and outstanding Common Stock immediately prior to the Effective Time are automatically combined

into one (1) validly issued, fully paid and nonassessable share of Common Stock, par value $0.007 per share (the “Reverse Stock

Split”). Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, any

person who would otherwise be entitled to a fractional share of Common Stock as a result of the reclassification and combination following

the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder) shall be entitled

to receive a cash payment equal to the number of shares of the Common Stock held by such stockholder before the Reverse Stock Split that

would otherwise have been exchanged for such fractional share interest multiplied by the average closing sales price of the Common Stock

as reported on the Nasdaq Capital Market for the ten (10) days preceding the Effective Time.

Each stock certificate or book-entry position

that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to

the Effective Time shall, from and after the Effective Time, automatically and without the necessity of presenting the same for exchange,

represent that number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented

by such certificate or book-entry position shall have been reclassified and combined (as well as the right to receive cash in lieu of

fractional shares of Common Stock after the Effective Time).”

4. This amendment was duly adopted

in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

5. All other provisions of the

Certificate of Incorporation shall remain in full force and effect.

IN WITNESS WHEREOF, the Corporation

has caused this Certificate of Amendment to be signed by Maria Zannes, its President and Chief Executive Officer, this 20th

day of August 2026.

/s/

Maria Zannes

Maria

Zannes

President

and Chief Executive Officer

-1-

EX-99.1

Filename: ex99-1.htm · Sequence: 3

Exhibit 99.1

bioAffinity

Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

SAN

ANTONIO, TX – August 20, 2026 – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company

focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse

split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on August 24, 2026, the Company’s

common stock will trade on a post-split basis under the symbol BIAF. The reverse stock split was approved by the Company’s stockholders

at the Company’s annual meeting held on April 30, 2026.

a result of the reverse stock split, the CUSIP number for the Company’s common stock will now be 09076W406. As

a result of the reverse stock split, every 15 shares of issued and outstanding common stock will be exchanged for one share of common

stock. Any stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. Immediately

after the reverse stock split becomes effective, the Company will have approximately 592,373 shares of common stock issued and outstanding.

The

reverse stock split is primarily intended to bring the Company into compliance with Nasdaq’s minimum bid price requirement.

a result of the reverse stock split, proportionate adjustments will be made to the per-share exercise prices of, and the number of shares

underlying, the Company’s outstanding stock options, as well as to the number of shares available for future awards granted under

the Company’s stock incentive plans. In addition, proportionate adjustments will be made to the per-share exercise prices of, and

the number of shares underlying, outstanding warrants to purchase shares of the Company’s common stock. The CUSIP number for the

Company’s publicly traded warrants will not change as a result of the reverse stock split.

The

combination of, and reduction in, the issued shares of common stock as a result of the reverse stock split will occur automatically at

the effective time of the reverse stock split without any additional action on the part of the Company’s stockholders. The Company’s

transfer agent, VStock Transfer LLC, is acting as the exchange agent for the reverse stock split and will send stockholders of record

holding their shares electronically in book-entry form a transaction notice indicating the number of shares of common stock held after

the reverse stock split, along with a cash payment in lieu of any fractional shares, in accordance with the processes at their respective,

bank, broker or nominee.

-1-

Additional

information concerning the reverse stock split can be found in the Company’s definitive proxy statement filed with the Securities

and Exchange Commission on June 2, 2025.

About

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW)

bioAffinity

Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum

cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity,

specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed

Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Forward-Looking

Statements

Certain

statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.

Words such as “may,” “might,” “will,” “should,” “believe,” “expect,”

“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”

“plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are

forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements

regarding the potential impacts of the reverse stock split on the market price of the Company’s

common stock, the potential decreased liquidity in the Company’s common stock following the reverse stock split, and the

potential dilutive effects of future financings following the reverse stock split. These forward-looking statements are subject to various

risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations

and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results

to differ materially from current expectations include, among others, the potential impacts of

the reverse stock split on the market price of the Company’s common stock, the potential decreased liquidity in the Company’s

common stock following the reverse stock split, the potential dilutive effects of future financings following the reverse stock split,

and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent

filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts

and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company

believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on

any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does

not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may

be required by applicable securities laws.

Contact

bioAffinity

Technologies

Julie

Anne Overton

Director

of Communications

jao@bioaffinitytech.com

-2-

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (6475 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 5

Binary file (3272 bytes)

Download ex99-1_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Aug. 20, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 20, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-41463

Entity Registrant Name

bioAffinity

Technologies, Inc.

Entity Central Index Key

0001712762

Entity Tax Identification Number

46-5211056

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3300

Nacogdoches Road

Entity Address, Address Line Two

Suite 216

Entity Address, City or Town

San

Antonio

Entity Address, State or Province

Entity Address, Postal Zip Code

78217

City Area Code

(210)

Local Phone Number

698-5334

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.007 per share

Title of 12(b) Security

Common

Stock, par value $0.007 per share

Trading Symbol

BIAF

Security Exchange Name

NASDAQ

Warrants to purchase Common Stock

Title of 12(b) Security

Warrants

to purchase Common Stock

Trading Symbol

BIAFW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue0.007PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=BIAF_WarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: